Avantor (AVTR) Q1 2025 earnings summary

Executive summary

• Q1 2025 net sales were $1.58B, down 6% year-over-year, with organic sales down 2% due to lower demand in Laboratory Solutions and the Clinical Services divestiture.

• Net income rose to $64.5M from $60.4M in Q1 2024, driven by lower SG&A and interest expenses, partially offset by pension charges.

• Adjusted EBITDA was $269.5M (17.0% margin), and adjusted EPS was $0.23, both in line with internal plans.

• Aggressive actions underway to accelerate growth in Lab Solutions, expand margins, and reduce leverage, including leadership changes and digital investments.

• Cost transformation initiative expanded, targeting $400M in run-rate gross savings by end of 2027.

Financial highlights

• Q1 reported revenue: $1.58B; organic revenue declined 2% year-over-year, mainly due to Lab Solutions underperformance and Clinical Services divestiture.

• Adjusted gross profit: $535M (33.8% margin), down 20 bps YoY; adjusted EBITDA: $270M (17% margin); adjusted operating income: $243M (15.4% margin).

• Adjusted EPS: $0.23, up from $0.22 YoY; free cash flow: $82M, impacted by one-time costs and working capital timing.

• Adjusted net leverage: 3.2x EBITDA, improved from 4.0x YoY.

• Cash and cash equivalents at quarter-end were $315.7M, with total liquidity of $1,442.1M.

Outlook and guidance

• FY 2025 organic revenue growth expected at -1% to 1%; reported revenue decline of -2% to flat due to divestiture and FX.

• Adjusted EBITDA margin guidance: 17.5%-18.5%; adjusted EPS: $1.02-$1.10; free cash flow: $650M-$700M.

• Q2 organic revenue expected flat to modestly up; Lab Solutions flat to modestly down, Bioscience Production up mid-single digits.

• Guidance assumes persistent macro and policy headwinds, with no material tariff impact included.

• Inflationary pressures and foreign currency fluctuations expected to continue impacting results.